Costly Assay Applications Prompt OIVD To Reconsider Bundling Policy
This article was originally published in The Gray Sheet
Executive Summary
FDA's Office of In Vitro Diagnostic Device Evaluation & Safety is showing a willingness to depart from bundling precedent in cases where user fee costs are overly burdensome to manufacturers and a premarket review package acceptable to OIVD divisions can be assembled
You may also be interested in...
FDA Guidances Outline User Fee Collection Policy, Small Business Criteria
Modular premarket applications will be exempt from device user fees if FDA received the initial module of the PMA prior to Oct. 1, 2002
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.